All News
Do patients with #SpA have a different phenotype if they have "root joint disease"?
Find out at the #EULAR2021 Poster Tour #POS0239
or at https://t.co/30JdHxTKus https://t.co/ocEefm8II9
Nelly ZIADE 🍀 Nellziade ( View Tweet)
@MeralElRamahiMD @RheumNow True that axSpA is diff from pts with peripheral SpA predominantly but isn’t it circular reasoning to say axial has more HLAB27+ as that is group in whom criteria were developed including HLAB27?
Janet Pope Janetbirdope ( View Tweet)
Don’t forget to use imaging that you already have!
CT Abd/Pelvis (ordered for nonMSK) of 301 IBD pts shows underlying sacroilitis
⭐️60/301 had sacroilitis on CT
⭐️11/60 had AxSpA
⭐️3/60 previously undiagnosed axSpA
Abs#POS0035
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi
➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l
#EULAR2021 @Rheumnow https://t.co/faT3M0xQiR
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus
⭐️⬇️AS activity w/ or w/o MRI sacroilitis
Abs#OP0142
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Bingo. It always had been rather odd to me that you would call someone nr-SpA when they had MR evidence of disease; xrays are not sensitive to pick up changes. While we're at it, can we just use the term "imaging" instead of "radiographs" with the availability of better tech? https://t.co/I6reoHyywf
k dao KDAO2011 ( View Tweet)
Filgotinib showed ⬇️ in spinal inflammation of AS pts after 12 weeks!
⭐️Subscores of the posterior elements, facet joints and vertebral bodies showed significant changes
⭐️no significant changes in spine fat, bone erosion or new bone formation
Abs#OP0141
#EULAR2021 @RheumNow https://t.co/tcBFuxnu4n
Robert B Chao, MD doctorRBC ( View Tweet)
Fatigue 35-80% of rheumatic pts! Excellent talk on fatigue in arthritis, SpA and systemic rheumatic disease! Abs#OP6875 #EULAR2021 @RheumNow
How do you help pts manage fatigue?
Robert B Chao, MD doctorRBC ( View Tweet)
➡️COMPLETE-AS = obs study of bDMARD-naive Canadians w/ active AS tx w/ ADA or nbDMARDS/NSAID.
➡️> overall⬇️in dz burden & shorter time to achieve therapeutic response w/ ADA. But, ADA pts had higher b/l dz
OP0143 #EULAR2021 @RheumNow https://t.co/FpJmugsdVw
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study?
⭐️187 bDMARD-naive, active AS pts w/ inadeq resp to NSAID
⭐️82-85% txed w/ UPA 15mg QD achieved BASDAI50 or ASDAS LDA over 64w
🚫 new safety signal & ZERO VTE, MACE, TB, or deaths w/ UPA.
OP0144 #EULAR2021 @RheumNow https://t.co/mFbgQjsD6f
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Interesting results from our post hoc analysis of #ASAS #PerSpA presented at #EULAR2021 by Dafne Capelusnik
⭐️Individual socioeconomic factors associated with poorer outcomes
⭐️Living in low GDP country associated with higher disease activity but paradoxically lower fatigue https://t.co/2SmKZPy8mw
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2021 PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate )
Dr. Rachel Tate reviews two abstracts - OP0051 and OP0049 - presented at the virtual EULAR 2021 meeting.
https://t.co/sUXTXDXrFh https://t.co/tQZktnlUXj
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
From bedside to bench–unexpected results of clinical studies that changed our understanding of the disease #EULAR2021.
“SpA” talk by Prof. Désirée van der Heijde.
Inhibition of TNF, IL-17, IL-23, IL-6, IL-1, co-stimulation and B cell depletion in immunology perspective 👏
/TK https://t.co/JFr3VC8sXY
ARD & RMD Open ARD_BMJ ( View Tweet)
PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate)
https://t.co/sUXTXDXrFh
Dr. John Cush RheumNow ( View Tweet)
TNFi use associated with ⬇️ radiographic sacroilitis progression in patients with AxSpA
⭐️effect becomes evident between 2 and 4 years after treatment
Abs#OP0137
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
SPACING trial OP0138 at #EULAR2021
⭐️RCT by the French showing non-inferiority of spacing TNFi in r-axSpA pts w/ LDA (BASDAI<4 x 6mo)
⭐️ 88% in spacing group remained w/ LDA vs 91.5% in standard tx
⭐️ADA, CTZ, GOL, IFX spaced by 1w intervals. ETN by 3-4d & 1w. @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
COAST-Y 2 yr results: In r- and nr-axSpA, IXE tx led to consistent & sustained long-term improvements in disease activity & QoL. No new safety signals. #EULAR2021 poster #POS0912 @RheumNow https://t.co/W2YoyA4K14 https://t.co/lv0GLU2WTF
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Dr Lukas presents data showing possibility of tapering a range of TNF in AxSpA patients in remission 162/184 (88.0%) LDA in progressive spacing group vs 173/189 (91.5%) in continued at 1 year.@RheumNow #EULAR2021 Abstr#0138
Richard Conway RichardPAConway ( View Tweet)
Abst#OP0137 at #EULAR2021:
➡️TNFi use for at least 1 year decreased radiographic sacroiliitis progression in early AxSpA in this ten year multicenter study of the German Spondyloarthritis Inception cohort (GESPIC) .
➡️This effect becomes evident 2-4 years after tx.
@RheumNow https://t.co/GNnYqYmxhl
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
